Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

Blood (2018) 132 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2018-99-117244

Published: 2018

Journal Articles

Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA

Florian Scherer, MD, David M. Kurtz, MD, Aaron M Newman, PhD, Alexander Craig, MPhil, Henning Stehr, PhD, Li Zhou, Cynthia Glover, Holbrook Kohrt, MD, Ronald Levy, MD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2016) 128 (22): 1752.

https://doi.org/10.1182/blood.V128.22.1752.1752

Published: 2016

Journal Articles

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

Blood (2016) 128 (22): 181.

https://doi.org/10.1182/blood.V128.22.181.181

Published: 2016

Journal Articles

Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens

Blood (2016) 128 (22): 915.

https://doi.org/10.1182/blood.V128.22.915.915

Published: 2016

Journal Articles

CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation and Blocking PD-1

Xing Zhao, Narendiran Rajasekaran, PhD, Uwe Reusch, PhD, Jens-Peter Marschner, MD, Martin Treder, Holbrook Kohrt, MD

Blood (2015) 126 (23): 2747.

https://doi.org/10.1182/blood.V126.23.2747.2747

Published: 2015

Journal Articles

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

Xing Zhao, Narendiran Rajasekaran, PhD, Uwe Reusch, PhD, Michael Weichel, Kristina Ellwanger, Jens-Peter Marschner, MD, Martin Treder, Holbrook Kohrt, MD

Blood (2015) 126 (23): 2763.

https://doi.org/10.1182/blood.V126.23.2763.2763

Published: 2015

Journal Articles

Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation

Boris Minev, MD, Holbrook Kohrt, MD, Mehmet Kilinc, PhD, Nanhai Chen, PhD, Audrey Feng, Maysam Pessian, Ulrike Geissinger, Erik Haefner, Desislava Tsoneva, Kliment Bozhilov, Idit Sagiv Barfi, PhD, Xing Zhao, Narendiran Rajasekaran, PhDMSc, Ronald Levy, MD, Aladar Szalay, PhD

Blood (2014) 124 (21): 4487.

https://doi.org/10.1182/blood.V124.21.4487.4487

Published: 2014

Journal Articles

Ibrutinib Enhances the Anti-Tumor Immune Response Induced By Intratumoral Injection of a TLR9 Ligand

Idit Sagiv-Barfi, Holbrook Kohrt, MD, Laura Burckhardt, Debra K Czerwinski, Ron Levy, MD

Blood (2014) 124 (21): 3121.

https://doi.org/10.1182/blood.V124.21.3121.3121

Published: 2014

Journal Articles

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Blood (2012) 119 (17): 4083–4090.

https://doi.org/10.1182/blood-2012-02-409763

Published: 2012

Journal Articles

A CpG-loaded tumor cell vaccine induces antitumor CD4 + T cells that are effective in adoptive therapy for large and established tumors

Matthew J. Goldstein, Bindu Varghese, Joshua D. Brody, Ranjani Rajapaksa, Holbrook Kohrt, Debra K. Czerwinski, Shoshana Levy, Ronald Levy

Blood (2011) 117 (1): 118–127.

https://doi.org/10.1182/blood-2010-06-288456

Published: 2011

Includes: Supplemental data

Journal Articles

Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity

Holbrook Kohrt, MD, Brit Turnbull, PhD, G. Laport, MD, D. Miklos, MD, PhD, J. Shizuru, MD, PhD, L. Johnston, MD, S. Arai, MD, W. K. Weng, MD, PhD, J. Benjamin, MD, PhD, K. Blume, MD, R. Negrin, MD, P. Lavori, PhD, S. Strober, MD, R. Lowsky, MD

Blood (2008) 112 (11): 3310.

https://doi.org/10.1182/blood.V112.11.3310.3310

Published: 2008

NARROW

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens

CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation and Blocking PD-1

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation

Ibrutinib Enhances the Anti-Tumor Immune Response Induced By Intratumoral Injection of a TLR9 Ligand

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

A CpG-loaded tumor cell vaccine induces antitumor CD4 + T cells that are effective in adoptive therapy for large and established tumors

Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only